. Some patients also develop benign plexiform neurofibromas, which can cause substantial morbidity and can degenerate to form peripheral nerve sarcomas known as malignant peripheral nerve sheath tumours (MPNSTs). These tumours are key contributors to reduced life expectancy in NF1 (REF. 6 ). Another com mon tumour in patients with NF1 is optic pathway gli oma (OPG) 7 . In 1988, a US National Institutes of Health (NIH) consensus conference defined the currently used NF1 diagnostic criteria 8, 9 . Notably, these criteria include neurofibroma and OPG but do not include malignant disease. Rarer tumours that develop in patients with NF1 are juvenile myelomonocytic leukaemia (JMML) 10 , benign or malignant pheochromocytoma 11 , gastro intestinal stromal tumour (GIST) 12 , glomus tumours 13 , juvenile xanthogranuloma, rhabdomyosarcoma 14 and lipoma 15 . Cloning of the NF1 gene (OMIM 613113) led to the identification of biallelic NF1 mutations in patientderived tumours, which in turn immediately led to classification of NF1 as a tumour suppressor gene [16] [17] [18] . All NF1related tumours show biallelic inactivation of the NF1 gene 19, 20 . Patients with NF1 may also be at an increased risk of developing secondary cancers following radiation exposure, and it is important to consider this risk in the treatment of this predisposed population 21 . In addition, patients with NF1 have an increased risk of developing several adult cancers 22 . An analysis of UK death certificates found that patients with NF1 may also be at an increased risk of cancers of the gastrointestinal tract, liver, lung, bone, thyroid, breast and ovary 22 . Risk of malignant melanoma, nonHodgkin lymphoma and chronic myeloid leukaemia might also be increased.
Early studies identified the protein encoded by NF1, neurofibromin, as having homology to the yeast proteins Ira1 and Ira2, which are inhibitory regulators of the RAS-cyclic AMP pathway [23] [24] [25] . In yeast, Ira pro teins negatively regulate Ras by converting it from the active GTPbound form to the inactive GDPbound form. This is required to reduce levels of cAMP under nutrientlimiting conditions and to mediate membrane association of adenylyl cyclase. Neurofibromin is a GTPaseactivating protein (GAP) that regulates RAS (RASGAP). It binds to GTPbound RAS through its GAPrelated domain (GRD) to dramatically augment its intrinsic GTPase activity 26 . Neurofibromin thereby functions as an off signal for all of the vertebrate RAS GTPases, including HRAS, NRAS, KRAS, MRAS, RRAS and RRAS2 (also known as TC21) 27 . Therefore, loss of NF1 activates signalling through the RAS path way, which is a key driver of cancer. GTPbound RAS The range of cancers associated with NF1 identified in a Danish population 184 • Drosophila Nf1 mutant reported 189, 190 • NF1-associated disease manifestations confirmed in a large study 4 Demonstration that some mouse and human neurofibromas can shrink in response to imatinib 119, 152 Cloning of the human NF1 gene at chromosome 17q22.1 by Wallace et al. 18 and Viskochil et al. 16 and the mouse Nf1 gene at chromosome 11p by Neal Copeland and colleagues 187 MEK inhibition shows singleagent efficacy against neurofibromas and JMML in GEM models, which supports clinical trials 86, 151 Friedrich von Recklinghausen monograph describes NF1
(REF. 183) • US NIH consensus conference defines NF1 diagnostic criteria 8 • Vincent Riccardi carries out the first NF1 clinical trial, using a mast cellstabilizing agent 185 Mouse knockout of the Nf1 gene resulted in embryonic lethality 149, 188 Increasing proteotoxic stress in combination with rapamycin therapy induced tumour regression in MPNSTs in GEM models 133 Zebrafish Mutations in many other genes that encode com ponents of the RAS-MAPK pathway also predispose patients to partially overlapping sets of manifestations (known as RASopathies), which can include tumours 29
. Patients with Noonan syndrome have a 4% risk of developing cancer by the age of 20 years, with JMML predominating and rhabdomyosarcoma, neuroblastoma and lowgrade glioma occurring at lower incidences 30 . Patients with Costello syndrome have a 15% risk of cancer by the age of 20 years, with rhabdomyosarcoma developing in 9% of patients, and neuroblastoma and bladder cancer developing in 1% of patients 30 . Patients with Legius syndrome develop lipoma 31 . The fact that all known RASopathy mutations affect the RAS-MAPK signalling pathway supports the idea that the MAPK pathway downstream of RAS, and not other pathways downstream of RAS, is the crucial driver of tumori genesis in patients with RASopathies. 'RASopathy clin ics' are beginning to study and compare patients with RASopathies. It is hoped that some or all RASopathy manifestations will respond to therapies such as MAPK inhibitors.
Importantly, sequencing of tumour exomes and genomes has revealed that somatic NF1 mutations are present at incidences from 2.5% to 11.8% in sporadic, predominantly adult, tumour types such as lung cancer 32 , glioblastoma 33 , ovarian cancer 34 , breast cancer 35 and acute myeloid leukaemia (AML) 36 ; however, they are also present in the paediatric tumour rhabdomyosarcoma.
NF1 genetics: mutations and modifiers
Structure of the NF1 gene and mutational analysis. The NF1 gene contains 60 exons and generates multiple alternatively spliced isoforms 37 . More than 1,400 muta tions in the NF1 gene have been reported in the Human Gene Mutation Database, most of which are clearly lossoffunction alleles. These include splice site, non sense and missense mutations, as well as deletions, insertions, frameshifts and translocations 38 . Notably, several patient missense mutations that affect the neuro fibromin GRD selectively diminish GAP activ ity, which supports the notion that the regulation of RAS has a crucial role in NF1 disease 39 . Identification of NF1 mutations in patients remains difficult owing to the large gene size and structure, as well as the large range of mutations that have been identified 40 . For many years, 95% of patient mutations were identified using a combination of comple mentary methods, including protein truncation, fluorescence in situ hybridization, hetero duplex, Southern blot and cytogenetic analyses 38 .
A preliminary report applied nextgeneration sequenc ing to samples from patients with NF1 (REF. 41), and DNAbased sequencing is now being offered as a clinical test for diagnostic purposes (see the website of University of Alabama at Birmingham Medical Genomics Laboratory). Thus, NF1 mutation analysis can assist in diagnosing cases of NF1 in which a clinical diagnosis cannot be established with certainty.
The variability in manifestations in patients from a single family with the same NF1 mutation does not sup port a major role for genotype-phenotype correlations in NF1 (REF. 42 ), although there are several important exceptions. Germline splice site mutations occur in 30% From the development of diagnostic criteria to the development of ongoing clinical trials, the neurofibromatosis type 1 (NF1) field has been aided by close clinician-scientist interactions, which have been facilitated by the Children's Tumor Foundation. Currently accepted diagnostic criteria include six or more café-au-lait macules with a minimum diameter of >5 mm in pre-pubertal subjects; two or more neurofibromas of any type or one plexiform neurofibroma; freckling in the axillary or inguinal region; optic pathway glioma; two or more Lisch nodules (iris hamartomas); a distinctive osseous lesion, such as sphenoid dysplasia or thinning of long bone cortex with or without pseudarthrosis; and a first-degree relative with NF1 according to these criteria. GEM, genetically engineered mouse; JMML, juvenile myelomonocytic leukaemia; MPNSTs, malignant peripheral nerve sheath tumours; NIH, National Institutes of Health. Nature Reviews | Cancer 
Café-au-lait macules
Hyperpigmented spots on the skin of patients with neurofibromatosis type 1 (NF1). They are used as an NF1 diagnostic criterion, particularly in young children.
Polycomb repressive complex 2
A complex that regulates epigenetic silencing of chromatin and includes the subunits SUZ12, EED, EZH1 or EZH2 and RBAP48. It also has histone methyltransferase activity.
Astrocytes
The most abundant type of glial cell in the central nervous system. Astrocytes regulate the extracellular neuronal environment.
of patients with NF1, and these patients may have an increased overall tumour risk 43 . Mutations that delete the NF1 gene, and several flanking genes, occur in up to 10% of patients with NF1. This class of mutations predisposes affected individuals to an increased risk of intellectual disability, to greater numbers of cutaneous neurofibro mas and to MPNSTs 44 . Another genotype-phenotype correlation is of a very rare 3bp deletion in patients with NF1 who lack neurofibromas 45 .
Modifier genes in NF1. Given the paucity of NF1 gen otype-phenotype correlations, it was proposed that modifier genes underlie the variable penetrance of NF1. Monozygotic twins with NF1 showed a high degree of concordance for cutaneous neurofibroma tumour burden and numbers of café-au-lait macules, support ing the idea that modifier genes contribute to these features 46, 47 . The large polygenic deletions (mentioned above) indicate that modifier genes might be linked to NF1 (REF. 44 ). Recently, the gene encoding the chroma tin remodelling complex Polycomb repressive complex 2 subunit SUZ12, which lies within this region, has been shown to be a cooperating tumour suppressor in mouse models and in human tumours [48] [49] [50] . Studies in mouse models also support roles for modifier genes in NF1. Astrocytoma resistance alleles were recently iden tified as spinal cord resistance to astrocytoma modi fier 1 (Scram1) and astrocytoma resistance locus in males 1 (Arlm1) loci 38, 51, 52 . It is unclear whether disease modifier genes in NF1 are also relevant in NF1mutant sporadic tumours.
In support of a role for modifier genes in NF1 is OPGs; these tumours have a decreased prevalence in the AfricanAmerican population compared with other races 53 . Sexlinked factors may modify prognosis; males are at an increased risk of sporadic highgrade glioma, but NF1 females with lowgrade OPG have a worse progno sis than males with NF1related OPG 54 . In addition, male Nf1 -/-mouse astrocytes expressing dominantnegative p53 show increased tumorigenesis and inactivation of the RB protein compared with cells derived from females 55 . An imprinting control region remotely interacts with an intergenic sequence between Nf1 and Wsb1 on chromo some 11 to regulate Nf1 transcription, and mutations in this intergenic sequence could also potentially modify NF1 disease 56 .
NF1 mutations in sporadic cancers. The advancement of wholegenome sequencing has resulted in the identifica tion of NF1 mutations in various nonNF1associated sporadic cancers, including glioblastoma 33, 57 , neuro blastoma 58 , AML 36 , lung cancer 32 , ovarian cancer 34 and breast cancer 59 . We anticipate that the identification of tumours that contain NF1 mutations will continue to increase with future sequencing efforts. A comprehen sive study that analysed somatic mutation patterns in more than 1,500 cancerrelated genes in a large panel of lung, breast, ovarian, pancreatic and prostate tumours identified NF1 (mutation frequency >5%) as one of ten genes that are mutated most often in these types of tumours. In comparison, the point mutation fre quency was 33% for TP53, 7% for KRAS and 5% for cyclindependent kinase inhibitor 2A (CDKN2A) 59 ; however, deletions in CDKN2A are much more com mon than deletions in NF1. It is as yet unknown whether biallelic loss of NF1 is common or whether only hemi zygous loss of NF1 contributes to tumour progression in sporadic disease. Consistent with the latter possibility, mouse cells hemizygous for Nf1 mutations show abnor mal growth and invasion [60] [61] [62] . Hemizygous NF1mutant cells might show lower levels of GTPbound RAS than cells with complete inactivation of NF1 and/or develop muta tions in additional RAS-MAPK pathway genes to affect tumour properties. Although sporadic tumours with NF1 mutations are largely exclusive of those tumours that harbour mutations in MAPK kinase 1 (MAP2K1) or NRAS, on the basis of our analyses of somatic co mutation patterns in The Cancer Genome Atlas data sets (cBio Portal for Cancer Genomics), 11 of 114 melano mas with NF1 mutations also show mutations in BRAF, NRAS or RAF1. Thus, there may be subcategories of tumours, and perhaps cells, in which BRAF, NRAS or RAF1 are comutated with NF1. Most plexiform neurofibromas are present at a very young age but, depending on the tumour location, may not be diagnosed until later in life if whole-body magnetic resonance imaging is not performed 192 . Multiple hyperpigmented skin lesions (café-au-lait macules) are an early sign of neurofibromatosis type 1 (NF1) and are observable in children under 3 years of age 193 . Young children may also present with bone dysplasia 194 , delayed speech 195 and delayed acquisition of motor skills 196 . Young children with NF1 are at an increased risk of developing juvenile myelomonocytic leukaemia (JMML) 10 and optic pathway glioma (mean age of 5 years
197
). Later in childhood, cognitive issues surface 198 . If the features labelled in burgundy do not occur early, they will not develop later in life. The dark blue line shows that speech, language, motor and cognitive changes are detected, as children would normally develop specific skills. Cutaneous neurofibromas typically begin to grow during puberty 5 . Although malignant peripheral nerve sheath tumours (MPNSTs) may occur in childhood, they are most common in adult patients with NF1 over 30 years of age 124 . Beyond cancer, it is now appreciated that generalized or specific cognitive impairment is observed in >50% of patients with NF1 (REF. 198 ), and many have attention deficit hyperactivity disorder. Features of autism spectrum disorder may occur 199 , and vascular defects are common 200 .
On the basis of cloning of the NF1 gene, understanding of the related disorders and clarification of age-of-onset of individual disease manifestations, it has been suggested (since 2007) that the diagnostic criteria may need revision 201 . Nature Reviews | Cancer
Imprinting control region
A regulatory element (a segment of DNA) that is modified by methylation to regulate gene expression.
In tumours with NF1 mutations, the order of muta tions seems to affect tumour grade in specific cell types; for example, initial loss of NF1 in nerve glial cells triggers neurofibroma. In this case, oncogeneinduced senescence occurs, and inactivation of p53 bypasses this response for progression to MPNSTs 63 . Similarly, benign grade 1 astro cytomas develop in genetically engineered mice (GEMs) when Nf1 is lost first 64 . By contrast, aggressive gliomas form when Trp53 is comutated with Nf1 (REF. 65 ). Indeed, in human glioblastomas, half of the tumours with NF1 muta tions also harbour TP53 mutations 66 . Mutational order may explain why patients with NF1 are not predisposed to certain sporadic tumours, such as lung tumours, whereas >10% of sporadic lung cancers 32 have NF1 mutations, which are probably acquired late in tumorigenesis.
The NF1 protein: neurofibromin Neurofibromin is a large multidomain 2,818 amino acid protein 67 . Exon 23 encodes part of the GRD, which is the RAS regulatory domain of neurofibromin. An exon 23 splice variant inserts an alternative exon 23a, which decreases neurofibromin RASGAP activity 68 . In addition to this central GRD, neurofibromin contains other functional domains, most of which are of uncer tain importance in the tumour suppressor function of neurofibromin (FIG. 4) .
Interactions of neurofibromin. In 1991, Bollag and
McCormick 69 reported that the lipids arachidonate, phosphatidate and phosphatidylinositol4,5bisphosphate inhibit neurofibromin GAP activity, but no definitive in vivo role for lipid-neurofibromin interaction through the SEC14 and pleckstrin homology (PH) domains has so far been identified. Neurofibromin is also implicated in connecting RAS signalling to activation of RHOfamily GTPases, which results in modulation of the cytoskeleton. Therefore, it is intriguing that the neurofibromin phospholipidbinding SEC14 and PH domains interact with LIM domain kinase 2 (LIMK2) and thereby inhibit activation of LIMK2 by RHOassociated protein kinase, which is known to modulate the actin cytoskeleton 70 . Some neurofibromin domains may function as scaf folds that target neurofibromin to specific intracellular locations. Indeed, neurofibromin interacts with sprouty related, EVH1 domaincontaining protein 1 (SPRED1). This interaction results in localization of neurofibromin to membranes, which enables neurofibromin to down regulate GTPbound RAS 71 . Interestingly, SPRED1 is also a RASopathy gene. Unlike mutations in NF1, mutations in SPRED1 do not predispose affected individuals to neuro fibromas, gliomas or MPNSTs but rather to lipo mas. Distinct features of each disorder may arise from cell typespecific use of components of the MAPK pathway.
Neurofibromin is the main RASGAP in neuronal dendritic spines 72 , where the molecular chaperone valosincontaining protein (VCP) interacts with the leucinerich repeat domain of neurofibromin. In mice, mutations in Vcp, like loss of Nf1, reduce spine density 73 . Importantly, VCP functions downstream of neuro fibromin, and expression of VCP rescues spine defects in Nf1 +/-neurons. VCP is now under investigation as a cancer target. Dimethylarginine dimethylaminohydro lase 1 (DDAH1), which degrades the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA), was identified as another neurofibromin inter action partner. Knockdown of Nf1 rescued the decrease in cell proliferation caused by knockdown of Ddah1 in mouse endothelial cells 74, 75 , and this is of special interest because the modulation of nitric oxide is an attractive therapeutic target.
Neurofibromin regulation and signalling
Neurofibromin protein levels can also be affected by mechanisms beyond NF1 mutation. One category of neurofibromininteracting proteins is ubiquitin ligases, which ubiquitylate and cause degradation of neuro fibromin, thus sustaining RAS signalling. The ubiqui tin ligase SAG (sensitive to apoptosis gene protein; also known as RNF7 and RBX2) was reported to interact with neurofibromin and affect vascular development 76 , whereas the ubiquitin ligase cullin 3 degraded neuro fibromin in glioblastoma cells in which neurofibro min was not mutated 76, 77 . It remains to be determined whether these and/or other ubiquitin ligases only degrade neuro fibromin in specific settings. Downregulation of neuro fibromin may also result from the methylation of NF1 in cancer cells 78, 79 . NF1 is also a target of micro RNAs (mi RNAs); expression of miR128 in neurons and miR193b in head and neck squamous cell carcinoma cells decreased the levels of NF1 mRNA and neurofibromin 80, 81 .
Modulation of RAS signalling by neurofibromin. The absence of neurofibromin leads to slowed hydrolysis of GTPbound RAS, which sustains RAS signalling. Nevertheless, upstream receptors are required to activate RAS, and several receptors have been implicated upstream of neurofibromin in particular cell types. For example, Figure 3 | Neurofibromatosis type 1 signalling pathways. In the absence of negative regulation of RAS proteins, resulting from loss of neurofibromatosis type 1 (NF1, which encodes neurofibromin), GTP-bound RAS levels are increased. Therefore, signalling pathways downstream of RAS that are normally activated by receptorsincluding receptor tyrosine kinases, integrins and ion channels -show enhanced activation. RAS signalling pathways include the MEK-ERK signalling cascade downstream of RAF and also many other potential RAS effectors, including AF6, an F-actin and RAP1-binding protein; RAL guanine nucleotide dissociation stimulator (RALGDS), a guanine nucleotide exchange factor (GEF) for the RALA and RALB GTPases; T lymphoma invasion and metastasis-inducing protein 1 (TIAM1), an exchange factor for the GTPase RAC1; phospholipase Cε (PLCε), an isoform of the phospholipase C family; and RAS and RAB interactor 1 (RIN1), which is a RAS effector and RAB5 GEF. In addition, loss of NF1 results in deregulation of cyclic AMP levels in affected cells through poorly characterized mechanisms that may be independent of RAS and/or result from crosstalk between RAS and heterotrimeric G protein signalling. RAF and cAMP are the only effector pathways currently shown to have therapeutic potential in NF1 disease. GAP, GTPase-activating protein. . This receptor may also have a role in neurofibroma formation after nerve injury 83 . By contrast, activation of the KIT receptor by stem cell factor (also known as KIT ligand) has a key role in neurofibroma formation in mice 62 . In Drosophila melanogaster expressing mutant Nf1, the loss of the recep tor tyrosine kinase Anaplastic lymphoma kinase (Alk) rescues the small size of the flies and ERK activation 84 .
Other receptors probably function as upstream regulators of neurofibromin in specific cell types.
Neurofibromin and downstream signalling. Of the many putative downstream effectors of RAS signalling -RAL guanine nucleotide dissociation stimulator (RALGDS), PI3K, phospholipase Cε, T lymphoma invasion and metastasisinducing protein 1 (TIAM1), RAS association domain family protein (RASSF), RAS and RAB inter actor 1 (RIN1), RIN2, RIN3, AF6 (also known as afadin and MLLT4), impedes mitogenic signal propagation (IMP; also known as BRAP2), RASassociated and PH domainscontaining protein 1 (RAPH1), growth factor receptorbound protein 7 (GRB7), and PDZGEF1 (also known as RAPGEF2) (FIG. 2) -only a few have been studied in the context of NF1. The best studied is the neurofibromin-RAS-MAPK pathway. Loss of neuro fibromin results in the activation of this pathway in multiple types of tumour 85, 86 . Heat shock response 87 . PI3K-AKT signalling downstream of Rras2 has a role in the initiation of neurofibromas 92 ; activation of the PI3K pathway through loss of Pten in mice promotes the transformation of Nf1driven neurofibromas to MPNSTs 93 . Sustained activation of AKT in MPNST cells requires calcium and calmodulin 94 . On the basis of these results, it will be important to consider cell typespecific neurofibromin-RAS effector pathways when attempt ing to identify therapeutic targets. In addition, simulta neously targeting multiple RAS effector pathways may provide enhanced effects.
NF1 and cAMP.
In yeast, the NF1 homologues IRA1 (REF. 95 ) and IRA2 (REF. 96 ) regulate both Ras and cAMP signalling. Ira1 and Ira2 each simultaneously bind to Ras2 and adenylyl cyclase, thus regulating both path ways 97 . It is accepted that increased levels of cAMP inhibit the proliferation of most cell types, and it has been proposed that altered levels of cAMP contribute
Box 1 | RASopathy genes and syndromes
RASopathies commonly predispose patients to short stature, developmental delay and cardiac abnormalities 29 . The syndrome (or syndromes) associated with each gene (or genes) is indicated by light grey arrows in the figure. RASopathies include the common disorders neurofibromatosis type 1 (NF1; which affects 1 in 3,000 individuals) and Noonan syndrome (which affects 1 in 2,000 individuals) and rare conditions, such as Costello syndrome. Mutations in several RAS-MAPK genes can cause Noonan syndrome, Noonan syndrome with multiple lentigines (NSML; previously known as LEOPARD syndrome) and cardio-facio-cutaneous (CFC) syndrome. Other RASopathies, including NF1, are associated with a single gene mutation. Legius syndrome is associated with mutations in sprouty-related, EVH1 domain-containing 1 (SPRED1), and capillary malformation-arteriovenous malformation (CM-AVM) is associated with mutations in RASA1 (which encodes p120GAP). RASopathy genes include protein tyrosine phosphatase non-receptor type 11 98, 102 . In another system, the protein kinase Aactivated transcription factor cAMP responsive elementbinding protein (CREB) bound to the mir9 promoter, which repressed expression of NF1 and encouraged cell migration 103 . Interfering with cAMP signalling may present a therapeutic opportunity in several manifestations of NF1, as was proposed for NF1driven brain tumours 104 . Blocking RAS-MAPK sig nalling and increasing cAMP levels may be useful ther apeutically; for example, reversing one zebrafish brain defect required blockade of MEK, whereas reversing another defect required an increase in cAMP levels 100 .
NF1 tumorigenesis and tumour cells of origin
Many tumours in patients with germline NF1 mutations are neural crest cellderived tumours (pheochromo cytomas, neurofibromas and MPNSTs) or neuro epithelial cellderived tumours (pilocytic astrocytomas). Nonneuralcrestrelated cells are also predisposed to tumori genesis (JMML and rhabdomyosarcoma). It is not known why specific cell types are sensitive to loss of NF1. Affected populations do not express increased levels of neurofibromin compared with other cells; it has been speculated that these populations critically rely on neurofibromin rather than other GAPs.
Low-grade astrocytoma. At least 15% of patients with NF1 develop OPGs, which are mainly grade I pilocytic astrocytomas 7 . These tumours are defined as benign, generally have a favourable prognosis and rarely pro gress 105 . In contrast to NF1related pilocytic astrocyto mas, pilocytic astrocytomas in patients without NF1 are typically more aggressive, although they have RAS path way mutations, including BRAF duplications or activat ing point mutations in BRAF or KRAS 106 . In GEM models of grade 1 astrocytoma resulting from loss of Nf1, many neurons in the brain and most macroglial cells are Nf1 -/-owing to use of glial fibrillary acidic protein (Gfap)-Cre or brain lipidbinding protein (Blbp; also known as Fabp7)-Cre drivers, which excise Nf1 in most brain stem and progenitor cells 64, 98, 107 . The percentage of each cell type varies from tumour to tumour. Neurofibromas in the human dermis or epider mis (known as cutaneous or dermal neurofibromas) are benign and do not transform; however, they can cause a substantial cosmetic burden in patients. It has been a source of confusion that some plexiform neurofibromas, which are more aggressive than cutaneous neurofibro mas, also develop in the skin and subcutaneous tissue; alternative nomenclature has been discussed but not defined by consensus. There are no model organisms at present in which cutaneous neurofibromas sponta neously develop. However, after growth in vitro and transplantation into Nf1 +/-syngeneic hosts, skin hair folliclederived Nf1 -/-precursors (SKPs) formed tumours that resembled dermal neurofibromas 112 .
Transplantation of Nf1
-/-SKPs into pregnant female mice increased growth of neurofibromas in the mouse model 112 , and cutaneous neurofibromas can develop and grow dur ing puberty 5 and can increase in size and number during pregnancy 113 . However, it remains unclear whether and which hormones or other factors increase , a pleckstrin homology (PH) domain, a carboxy-terminal domain (CTD) and a syndecan-binding domain (SBD). The SEC14 and PH domains bind to phospholipids, and have been studied structurally 204 . Proteins identified as neurofibromin-interacting proteins and phospholipids (ovals) are shown associated with functions ascribed to them, including intracellular trafficking (light yellow); neuronal differentiation (dark yellow); membrane localization (dark blue); actin cytoskeleton remodelling (light pink); ubiquitylation (dark pink); cell adhesion (purple) and cell signalling through nitric oxide via dimethylarginine dimethylaminohydrolase 1 (DDAH1) and RAS (turquoise). Each interacting protein is shown bound to the domain of neurofibromin with which it is believed to interact. Some proteins are known to interact with neurofibromin, but the binding site is unknown. Phosphorylation (P) sites implicated as protein kinase A substrates are shown. Descriptions of each interacting protein, binding domains and literature references are shown in Supplementary information S1 (table) . APP, amyloid-β (A4) precursor protein; DPYSL2, dihydropyrimidinase-related protein 2; FAF2, FAS-associated factor 2; FAK, focal adhesion kinase; LIMK2, LIM domain kinase 2; LRPPRC, leucine-rich pentatricopeptide motif-containing protein; SCF, Skp, Cullin, F-box-containing complex; SPRED1, sprouty-related, EVH1 domain-containing protein 1; VCP, valosin-containing protein.
the growth of human cutaneous neurofibromas. It is also unclear which factors limit the growth of most dermal neurofibromas in humans, and why they are resistant to transformation.
Plexiform neurofibroma. Plexiform neurofibromas are complex tumours that can weigh kilograms and can compress vital structures. Therefore, they are of con siderable interest as targets of therapy. Plexiform neuro fibromas develop within peripheral nerves and their perineurial sheaths. However, plexiform neuro fibromas can invade adjacent tissue by disrupting the perineurium, remaining nonmetastatic and clinically 'benign' but accounting for substantial morbidity and an increased risk of mortality when symptomatic 114 . Extensive modelling of plexiform neurofibromas has been carried out in mice. Plexiform neurofibroma mod els all have biallelic loss of Nf1 in the Schwann cell line age [115] [116] [117] [118] , which is driven by P0 (also known as myelin protein zero (Mpz))-Cre, desert hedgehog (Dhh)-Cre, tamoxifeninducible proteolipid protein (myelin) 1 (Plp1)-Cre, or Krox20 (also known as Egr2)-Cre. Each of these drivers knock out expression in Schwann cell progenitors, with differences in precise timing, loca tion and the number of cells affected. Some models, probably those with fewer cells showing recombina tion, require additional hemizygous inactivation of Nf1 in haematopoietic cells to generate neurofibromas 119 . In all cases, the tumours (grade 1 neurofibromas) in GEM models resemble those of humans. In humans, plexiform neurofibromas primarily develop very early in life. Unexpectedly, plexiform neurofibromas can be induced even in adult mice, although in one model these are rare 116, 117 . Unfortunately, this result does not resolve the uncertainty around the plexiform neurofibroma cell of origin, as adult mouse dorsal root ganglia and dorsal roots contain stemlike cells, mature Schwann cells and satellite cells, all of which have been proposed as pos sible neurofibromainitiating cells [115] [116] [117] [118] 120 . Epidermal growth factor receptor (EGFR)expressing Schwann cell precursorlike cells are present in mouse and human neurofibromas, and form neurofibromalike lesions under the skin 120 126, 127 , and NF1 and sporadic MPNSTs share a gene signature 128 . MPNSTs are also typically hyperdiploid, and their genomes -like genomes in most sarcomas -are highly rearranged 129 .
Mutations associated with the transformation from benign plexiform neurofibromas to malignant MPNSTs include early mutations in CDKN2A 129 and later muta tions in TP53 and SUZ12 (REF. 133 ). Loss of the tumour suppressor gene RB1 (which encodes RB) is found in 25% of MPNSTs 134, 135 , and monosomy for the PTEN locus is observed in 50% of MPNSTs 126, 134, 136, 137 . Lowlevel amplification of growth factor receptor genes, including EGFR, is also common 126 . Human MPNSTs and MPNST cell lines contain CD133 + cells that may be stemlike cells 138, 139 . GEM models of MPNSTs include combined loss of Nf1 and Trp53 (REFS 140, 141) or Nf1 and Cdkn2a 142, 143 . MPNSTs from these models and human MPNST cell lines con tain stemlike cells that propagate disease 144 . Comparative oncogenomics and insertional mutagenesis screens have been used to identify candidate drivers of MPNST forma tion, including MEK, βcatenin and embryonic stem cell expressed RAS (ERAS) 86, 145, 146 . In zebrafish, ribosomal gene mutations predispose to the formation of MPNSTs, and resulting tumours show loss of p53 translation 147 .
Other tumours in patients with NF1. Pheochromo cytomas 11 , rhabdomyosarcomas 14 , glomus tumours 20, 148 and GISTs 12 are present at increased incidence in patients with NF1 and show biallelic inactivation of NF1. Of these, only pheochromocytoma has been suc cessfully modelled to date. Pheochromocytomas form in 15% of Nf1 +/-mice 149 ; however, this model has not been used in preclinical tests, probably owing to low tumour incidence. JMML is a rare paediatric mani festation of NF1 (REF. 10 ) and a RASdriven haema topoietic stem cell disorder. Thus, patients with NF1 and patients with RASopathies who have mutations in NRAS, KRAS, CBL, protein tyrosine phosphatase non receptor type 11 (PTPN11; also known as SHP2) or son of sevenless homologue 1 (SOS1) are predisposed to this lowgrade leukaemia 150 , which is recapitulated in an Mx1-Cre;Nf1 fl/fl model 151 .
Therapeutic implications Preclinical testing. Importantly, the available mouse models of JMML, OPG, plexiform neurofibroma and MPNST are currently used for preclinical testing. Consistent with a major role for RAS-MAPK signalling in JMML, preclinical testing showed significant response to inhibition of MEK 151 . Disease burden was markedly reduced, although mutant stem cells persisted. The finding that the multireceptor tyrosine kinase inhibi tor imatinib or inhibition of MEK can shrink plexiform neurofibromas in mouse models led to clinical tri als 86, 119, 151 . In the imatinib trial, 6 of 36 patients, primar ily young children with small plexiform neurofibromas, responded to treatment; the target kinase (or kinases) affected in these patients is not yet known 152 . In a Phase I trial of the MEK inhibitor selumetinib (presented at the 2014 American Society of Clinical Oncology meeting), 11 of 18 patients with plexiform neurofibromas, some up to kilograms in weight, shrank by ≥20% in response to therapy, and many showed prolonged response 153 . These positive results not only support continued use of mouse
Aurora kinase
A serine/threonine kinase that functions during mitosis and is required for correct function of centrosomes.
Bromodomain inhibitors
A new class of epigenetic modulators of gene expression. models to guide clinical testing in human neurofibro mas but also emphasize the finding that these benign tumours can respond to singleagent therapy for up to 3 years without showing resistance.
Complete surgical resection is required to cure MPNSTs, and no singleagent or combination tested to date has cured MPNSTs in any model system (reviewed in REF. 154 ). Consistent with the idea that combination therapy will be necessary to treat these aggressive cancers, the mTOR complex 1 (mTORC1) inhibitor rapamycin, together with agents that enhance oxidative stress, shrank MPNSTs
133
. In MPNST xenografts, prolonged responses have been observed with Aurora kinase inhibition and bromodomain inhibitors, but these have not yet been tested in mouse models of MPNSTs or in patients with NF1 (REFS 155, 156) . In some MPNSTs, autocrine chemokine (CXC motif) ligand 12 (CXCL12)-CXC receptor 4 (CXCR4) signalling activates βcatenin through the AKT-glycogen synthase kinase 3β-βcatenin stabiliza tion pathway 157 . Transposon mutagenesis confirmed WNT pathway signalling as a driver of the transforma tion to MPNSTs, and many βcatenin pathway genes are deregulated in neurofibroma and MPNSTs 158 . Although other links between NF1 signalling and βcatenin path way activation remain to be identified, these data and analysis of human NF1 Schwann cells support inhibition of the βcatenin pathway as a possible therapeutic target in NF1driven tumours 159 . NF1 loss as a drug resistance marker. MPNSTs in patients with NF1 are notoriously resistant to chemo therapy and radiation therapy. Recently, a largescale study showed almost no benefit of chemotherapy or radiotherapy for NF1 MPNSTs, and a worse outcome has been reported for NF1 than for sporadic MPNSTs 124 . These data must be interpreted with caution, as late diagnosis of MPNSTs arising in plexiform neurofibro mas in patients with NF1 may account for differences between the groups in treatment outcome 160 . However, although reasons might differ as to what causes resist ance in sporadic tumours, NF1 has been identified as a gene that confers resistance to targeted therapy, including inhibition of kinases and the RAS path way, in sporadic neuroblastoma 58 , lung carcinoma 161 and melanoma 162 . In lung cancer models, resistance to EGFR therapy was mediated by NF1, and blocking MEK restored the response 161 . Melanoma develops in mice with mutant Braf, and loss of Nf1 blocked Braf driven oncogeneinduced senescence. Nf1mutant and Brafmutant tumours are resistant to BRAF inhibitors; however, they are sensitive to combined inhibition of MEK and mTOR 162 . Loss of NF1 was also identified as a crucial mediator of resistance to BRAF inhibitors in melanoma cells 163, 164 . These studies indicate that block ing NF1 pathways -for example, by targeting MEK -might enhance the therapeutic response in those tumours with NF1 mutations. There are probably also other resistance pathways downstream of NF1. In a neuroblastoma model, resistance was mediated by NF1 through ZNF423, which encodes a zincfinger transcription factor 58 .
It is increasingly clear that the recruitment of mast cells, macrophages and other stromal cells in the tumour microenvironment can elicit tumour cell resistance to therapy 165 . NF1 -/-Schwann cells upregulate major histo compatibility complex class II mRNA and protein levels, which may influence tumour-immune cell inter actions 166 . Neurofibromas and MPNSTs contain blood derived mast cells 167 and macrophages 168 . The stroma in NF1 neurofibromas has been recently reviewed 169 . These haematopoietic cells have a crucial role in the formation and growth of neurofibromas. In some GEM models, the haematopoietic cells must express mutant Nf1 for neurofibromas to form 119 . Treatment with PLX3397 -which targets both KIT signalling to prevent mast cell recruitment to tumours, and CSF1 receptor signalling to prevent macrophage recruitment to tumours -had two effects on neurofibromas. It increased their size when given during tumour initiation and enabled tumour regression in some mice when given after tumour estab lishment. Therefore, macrophages may protect against developing tumours and later become permissive to tumour formation 168 . However, wounding peripheral nerves in Nf1mutant mice, which recruits macrophages, facilitates neurofibroma formation, implying that macro phages may promote tumour formation in this con text 83, 170 . OPGs that arise in Nf1mutant mice also contain CX3CR1expressing microglial cells (brainresident macrophages). Cx3cr1 -/-mice show delayed optic glioma formation, which supports interference with the micro environment as a possible therapy in patients with NF1 (REF. 171 ). In an MPNST xenograft, PLX3397 treatment resulted in macrophage depletion and substantially delayed MPNST growth. The effect was enhanced by the mTORC1 inhibitor rapamycin and correlated with enhanced depletion of macrophages 172 .
Discovering new drug targets for NF1-mutant cells.
Screening a library of 200,000 small molecules on mouse Nf1mutant MPNST cells identified compound 21, with selectivity towards NF1mutant cells and effi cacy in xenografts 173 . Another libraryscreening study identified UC1 as a small molecule that targets NF1 -/-versus sporadic MPNST cell lines. Budding yeast in which IRA2 was deleted validated selectivity of UC1 for NF1mutant cells 174 . Direct targets of these compounds are not known. Gene expression, methylome and copy number changes on several sample sets are publically available for neurofibromas and MPNSTs, and are being used to identify pathways and targets for drug discov ery 175 . Preliminary assessments of mi RNAs and serum biomarkers have also become available. Several proteins were identified either at increased levels in patients with NF1 but without neurofibromas (interferonγ, inter leukin6 and tumour necrosis factor) or at increased levels in patients with NF1 and MPNST (insulinlike growth factorbinding protein 1, CC motif chemokine 5 (CCL5) and adrenomedullin) 176, 177 . Expression of miR801, miR214 and miR24 can distinguish patients with both NF1 and MPNST from patients with NF1 but without MPNST 178 . However, no NF1 biomarker has yet been tested clinically.
Successes and future challenges The NF1 community has been very successful in iden tifying the NF1 gene and developing animal models for plexiform neurofibroma, MPNST and JMML. The community has also succeeded in identifying plausible therapeutic strategies and advancing them from preclinical testing to clinical trials, through preclinical and clinical testing consortia and a group developing end points for clinical trials 179 . However, some NF1driven cancers still lack model systems or have models that are difficult to use for preclini cal testing. Although the neurofibromin protein has been studied, many questions remain concerning the relevance of possible interaction partners and func tions of neurofibromin protein domains. Although it is now clear that the RAS-MAPK pathway is crucial for mediating NF1mutant tumour growth, other path ways downstream of RAS signalling are likely to be relevant and may be cell type dependent. In particu lar, an important goal of the next few years will be to better understand altered nonRAS-cAMP signalling downstream of NF1 loss. Identification of inhibitors of cell typespecific pathways that synergize with block ade of MEK, including inhibitors that target other RAS effector pathways, could be attempted. We anti cipate that therapies successful in treating NF1 disease manifestations will also be successful in the treatment of other RASopathies and hope that these therapies, in combination with other drugs, will also be useful in treating sporadic NF1mutant cancer.
